

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 May 2023 (04.05.2023)



(10) International Publication Number
WO 2023/073071 A1

(51) International Patent Classification:
C12N 15/86 (2006.01) A61P 1/00 (2006.01)

(21) International Application Number:
PCT/EP2022/080020

(22) International Filing Date:
26 October 2022 (26.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/263,175 28 October 2021 (28.10.2021) US

(71) Applicants: **UCB BIOPHARMA SRL** [BE/BE]; Al-
lée de la Recherche, 60, B-1070 Brussels (BE). **UCB**
BIOSCIENCES INC [US/US]; 1209 Orange Street, Wilm-
ington, Delaware 19801 (US).

(72) Inventors: **RODRIGUEZ ALVAREZ, Natalia**; c/o IPD,
UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB).
SIPEKY, Csilla; c/o IPD, UCB, 208 Bath Road, Slough
Berkshire SL1 3WE (GB). **VALLETTE, Brittany Nicole**;
c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL1 3WE
(GB). **WOLFF, Christian Gilbert Joseph**; c/o IPD, UCB,
208 Bath Road, Slough Berkshire SL1 3WE (GB). **XU,**
Meiyu; c/o IPD, UCB, 208 Bath Road, Slough Berkshire
SL1 3WE (GB).

(74) Agent: **UCB INTELLECTUAL PROPERTY**; c/o UCB,
208 Bath Road, Slough, Berkshire SL1 3WE (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

WO 2023/073071 A1

(54) Title: NUCLEIC ACID CONSTRUCTS, VIRAL VECTORS AND VIRAL PARTICLES

(57) Abstract: The present invention relates to a nucleic acid construct comprising a transgene encoding syntaxin binding protein 1 (STXBP1, Munc-18), a viral vector for packaging said nucleic acid in a viral particle; and use of such viral particle for treating disease associated with a loss of STXBP1 functional activity.